Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct;36(10):3276-82.
doi: 10.2337/dc13-0354. Epub 2013 Jul 8.

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

Sun H Kim  1 , Fahim Abbasi, Cindy Lamendola, Alice Liu, Danit Ariel, Patricia Schaaf, Kaylene Grove, Vanessa Tomasso, Hector Ochoa, Yeheng V Liu, Yii-Der Ida Chen, Gerald Reaven
Affiliations
Randomized Controlled Trial

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

Sun H Kim et al. Diabetes Care. 2013 Oct.

Abstract

Objective: The aim was to evaluate the ability of liraglutide to augment weight loss and improve insulin resistance, cardiovascular disease (CVD) risk factors, and inflammation in a high-risk population for type 2 diabetes (T2DM) and CVD.

Research design and methods: We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks. All subjects were advised to decrease calorie intake by 500 kcal/day. Peripheral insulin resistance was quantified by measuring the steady-state plasma glucose (SSPG) concentration during the insulin suppression test. Traditional CVD risk factors and inflammatory markers also were assessed.

Results: Eleven out of 35 individuals (31%) assigned to liraglutide discontinued the study compared with 6 out of 33 (18%) assigned to placebo (P=0.26). Subjects who continued to use liraglutide (n=24) lost twice as much weight as those using placebo (n=27; 6.8 vs. 3.3 kg; P<0.001). Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration. Inflammatory markers did not differ between the two groups, but pulse increased after liraglutide treatment (6.4 vs. -0.9 bpm; P=0.001).

Conclusions: The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD.

Trial registration: ClinicalTrials.gov NCT01784965.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of individuals who lost at least 5, 7, and 10% of baseline weight. Liraglutide treatment was associated with greater degree of weight loss compared with placebo.
Figure 2
Figure 2
Insulin resistance (SSPG) at baseline and after 14 weeks of liraglutide or placebo treatment. Insulin resistance significantly improved following liraglutide treatment but not placebo.
See this image and copyright information in PMC

References

    1. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006;48:293–297 - PubMed
    1. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010;33:2355–2359 - PMC - PubMed
    1. Association AD, American Diabetes Association Standards of medical care in diabetes—2013. Diabetes Care 2013;36(Suppl. 1):S11–S66 - PMC - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403 - PMC - PubMed
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350 - PubMed

Publication types

MeSH terms

Associated data